{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:51:16Z","timestamp":1772160676574,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2017,8,28]],"date-time":"2017-08-28T00:00:00Z","timestamp":1503878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Standard treatment for hepatic encephalopathy (HE) includes medications that reduce ammonia and bacterial translocation in the gut. Rifaximin can be used off\u2010label for the reduction of overt HE. The study purpose was to determine efficacy of traditional rifaximin dosing (400\u00a0mg three times daily) compared with newer dosing (550\u00a0mg twice daily) via readmission rates for the prevention of recurrent HE. This was a retrospective, observational, cross\u2010sectional pilot study conducted in a tertiary medical center. A total of 226 patients 18\u201389\u00a0years of age with documentation of HE via ICD\u20109 code who started rifaximin therapy while inpatient between April 2009 and June 2014 were evaluated. Data collected included rifaximin dosing, other medications used to treat HE, duration of therapy, time to readmission, and various laboratory values. There were no differences in readmission rates at 30\u00a0days, 60\u00a0days, or 6\u00a0months between treatment groups. Additionally, there was no difference in the odds of readmission between the treatment groups (OR\u00a0=\u00a00.77, 95% CI: [0.201, 4.365],\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.718). Patients had a low overall probability of readmission over the observational period. Based on average wholesale price data, the cost for a 9\u2010day supply of rifaximin for the 400\u2010mg dosing regimen is $952.56\n                    <jats:italic>versus<\/jats:italic>\n                    $605.16 for the 550\u2010mg dosing regimen. The rifaximin 550\u2010mg dosing strategy should be utilized in hospitalized patients for the prevention of recurrent HE as there was no difference in readmission rate or time to readmission between dosing groups. The 550\u2010mg regimen had a lower acquisition cost for a 9\u2010day duration of treatment in the studied institution.\n                  <\/jats:p>","DOI":"10.1111\/jgh.13759","type":"journal-article","created":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T11:36:49Z","timestamp":1486553809000},"page":"1548-1552","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Retrospective cross\u2010sectional pilot study of rifaximin dosing for the prevention of recurrent hepatic encephalopathy"],"prefix":"10.1111","volume":"32","author":[{"given":"Kelsey C","family":"Lyon","sequence":"first","affiliation":[{"name":"West Virginia University Healthcare Ruby Memorial Hospital  Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Likar","sequence":"additional","affiliation":[{"name":"West Virginia University Healthcare Ruby Memorial Hospital  Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay L","family":"Martello","sequence":"additional","affiliation":[{"name":"West Virginia University Healthcare Ruby Memorial Hospital  Morgantown West Virginia USA"},{"name":"Department of Clinical Pharmacy West Virginia University College of Pharmacy  Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Regier","sequence":"additional","affiliation":[{"name":"Department of Biostatistics West Virginia School of Public Health  Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,8,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907893"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27210"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.11.009"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.06.007"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.03.003"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00350-1"},{"key":"e_1_2_7_8_1","unstructured":"Rifaximin.Lexi\u2010Comp Online\u2122 Lexi\u2010Drugs Online Hudson Ohio: Lexi\u2010Comp Inc.; Accessed 1 November 2014."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X11401774"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.12.021"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.22172"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.314"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-11-149"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013080879"},{"key":"e_1_2_7_15_1","unstructured":"List of medicare severity diagnosis\u2010related groups (MS\u2010DRGS) relative weighting factors and geometric and arithmetic mean length of stay[table 5]. Centers for Medicare and Medicaid Services website:https:\/\/www.cms.gov\/Medicare\/Medicare\u2010Fee\u2010for\u2010Service\u2010Payment\/AcuteInpatientPPS\/FY2015\u2010IPPS\u2010Final\u2010Rule\u2010Home\u2010Page\u2010Items\/FY2015\u2010Final\u2010Rule\u2010Tables.html."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12970"},{"key":"e_1_2_7_17_1","volume-title":"RED BOOK Online\u00ae [Internet Database]","author":"Xifaxan"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjgh.13759","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgh.13759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T21:04:41Z","timestamp":1696194281000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jgh.13759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,28]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1111\/jgh.13759"],"URL":"https:\/\/doi.org\/10.1111\/jgh.13759","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727291251.793535963","asserted-by":"object"}]},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,28]]},"assertion":[{"value":"2017-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}